The CAR-T treatment kickoff meeting and academic seminar at Jinghu Hospital in Macau was held on the 11th, marking the entry of China's first approved CAR-T cell therapy product - Aquilencil Injection - into the Macau region, providing new treatment options and options for local blood tumor patients. Xie Xuebin, Vice President of Jinghu Hospital, expressed at the launch meeting that he is very pleased to see the application of CAR-T cell therapy technology in Jinghu Hospital. In the future, the treatment cycle of patients will be shortened, and the chances of cure are expected to increase. It is understood that CAR-T, also known as chimeric antigen receptor T cell immunotherapy, utilizes the patient's own immune cells to kill and clear cancer cells. In June 2021, Fosun Pharmaceutical's joint venture Fosun Kate's Aquilense Injection was approved for market launch in China. (Lai Xin She)